Prof. Dr. Markus Stoffel, M.D., Ph.D., serves as a Member of the Scientific Advisory Board of Alnylam Pharmaceuticals Inc., Regulus Therapeutics Inc. and PanCel Corporation. Prof. Dr. Stoffel serves as Heilbrunn Professor at Rockefeller University. He has been Full Professor of the Institute of Molecular Systems Biology at the ETH Zurich since July 15, 2006. He serves as a Member of the Scientific Advisory Board at Genfit SA. In 1995, he moved to the Rockefeller University as an Assistant Professor and Head of Laboratory of Metabolic Diseases. In 1999, he was appointed full Professor of Rockefeller University. His research focuses on the molecular and genetic mechanisms that regulate glucose and lipid homeostasis and that are dysregulated in complex human diseases such as type 2 diabetes. Prof. Dr. Stoffel received several honors for his work, including the Irma T. Hirschl Career Scientist Award in 1996; Pew Scholar Award in Biomedical Sciences in 1996; Career Development Award, American Diabetes Association in 1997; Bristol Myers Squibb Unrestricted Grant Award, Metabolism in 2002; Ernst Klenk Award in 2002; the Dorothy Hodgkin Award in Diabetes UK in 2005 and the Oustanding Scientific Research Award from the American Diabetes Association in 2006. In 2006 he was elected member of the Deutsche Akademie der Naturforscher Leopoldina. After a two-year residency in Internal Medicine at the Eppendorf Krankenhaus (Medical Center) in Hamburg, he spent three years as a postdoctoral fellow and Assistant Professor in the laboratory of Prof. G.I. Bell at the Howard Hughes Medical Institute at the University of Chicago, USA. Prof. Dr. Stoffel studied Medicine at the Universities of Cambridge, UK and Bonn, Germany.

  Internal Medicine